Global Bioburden Testing

Bioburden Testing Comprehensive Study by Type (Instruments, Consumables), Application (Medical devices, Pharmaceuticals, Packaging, Human Tissue, Animal Tissue, Cosmetics), Testing Type (Aerobic Count Testing, Anaerobic Count Testing, Fungi/Mold Count Testing, Spore Count Testing), End User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Contract Manufacturing Organizations, Manufacturers of Food & Beverage and Agricultural Products, Microbial Testing Laboratories) Players and Region - Global Market Outlook to 2026

Bioburden Testing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Bioburden Testing Market Scope
Bioburden testing, or total viable count testing, is the measure of microbial contamination levels on or in a product. Bioburden can be introduced from the raw materials used in the manufacturing process, or be introduced via the workforce or manufacturing environment. With numerous sources of contamination, the bioburden of a product can fluctuate between batches, so regular, routine testing is advisable. Bioburden testing is microbial testing performed on medical equipment and products used to measures the number of living organisms on the surface prior to final sterilization and use. Certain microbial levels are allowed during the handling of a product, and bioburden testing makes sure those limits are in force. It is usually performed before a large number of a product are manufactured so that the sterilization procedures can be implemented into the assembly process.

The Bioburden Testing market study is segmented by Type (Instruments and Consumables), by Application (Medical devices, Pharmaceuticals, Packaging, Human Tissue, Animal Tissue and Cosmetics) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Bioburden Testing market throughout the predicted period.

Sigma-Aldrich (United States), SGS S.A. (Switzerland), Becton Dickinson (United States), Nelson Laboratories (United States), ATS Labs (United States), Charles River (United States), Merck KGaA (Germany), WuXi AppTec (China), Thermo Fisher Scientific, Inc. (United States) and Biomérieux SA (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Pacific BioLlabs (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Bioburden Testing market by Type, Application and Region.

On the basis of geography, the market of Bioburden Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In February 2021 Element Materials Technology has acquired a leading pharmaceutical analytical testing company, Avomeen. Element’s existing network of life sciences laboratories offers a broad spectrum of testing services to the pharmaceutical, medical device and food segments and boasts a track record of high-level scientific expertise.
In January 2020 MilliporeSigma’s New Microbial Bioburden Testing System Milliflex Oasis Offers Enhanced Results and Increased Productivity. It offers enhanced benefits for pharmaceutical bioburden and water testing. It has 96 new features to increase result reliability and traceability while streamlining the bioburden testing workflow, the company reports.


Market Drivers
  • Increasing expenditure in the health care industries
  • Rising Safety Concerns Related to Food and Beverage Products

Opportunities
  • Emerging demand from the developing economies

Restraints
  • The high cost associated with the bioburden testing

Challenges
  • Lack of awareness regarding Bioburden Testing


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Bioburden Testing Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Type
  • Instruments
  • Consumables
By Application
  • Medical devices
  • Pharmaceuticals
  • Packaging
  • Human Tissue
  • Animal Tissue
  • Cosmetics
By Testing Type
  • Aerobic Count Testing
  • Anaerobic Count Testing
  • Fungi/Mold Count Testing
  • Spore Count Testing

By End User
  • Pharmaceutical & Biotechnology Companies
  • Medical Device Manufacturers
  • Contract Manufacturing Organizations
  • Manufacturers of Food & Beverage and Agricultural Products
  • Microbial Testing Laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing expenditure in the health care industries
      • 3.2.2. Rising Safety Concerns Related to Food and Beverage Products
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness regarding Bioburden Testing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bioburden Testing, by Type, Application, Testing Type, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Bioburden Testing (Value)
      • 5.2.1. Global Bioburden Testing by: Type (Value)
        • 5.2.1.1. Instruments
        • 5.2.1.2. Consumables
      • 5.2.2. Global Bioburden Testing by: Application (Value)
        • 5.2.2.1. Medical devices
        • 5.2.2.2. Pharmaceuticals
        • 5.2.2.3. Packaging
        • 5.2.2.4. Human Tissue
        • 5.2.2.5. Animal Tissue
        • 5.2.2.6. Cosmetics
      • 5.2.3. Global Bioburden Testing by: Testing Type (Value)
        • 5.2.3.1. Aerobic Count Testing
        • 5.2.3.2. Anaerobic Count Testing
        • 5.2.3.3. Fungi/Mold Count Testing
        • 5.2.3.4. Spore Count Testing
      • 5.2.4. Global Bioburden Testing by: End User (Value)
        • 5.2.4.1. Pharmaceutical & Biotechnology Companies
        • 5.2.4.2. Medical Device Manufacturers
        • 5.2.4.3. Contract Manufacturing Organizations
        • 5.2.4.4. Manufacturers of Food & Beverage and Agricultural Products
        • 5.2.4.5. Microbial Testing Laboratories
      • 5.2.5. Global Bioburden Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Bioburden Testing (Price)
      • 5.3.1. Global Bioburden Testing by: Type (Price)
  • 6. Bioburden Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sigma-Aldrich (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. SGS S.A. (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Becton Dickinson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Nelson Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ATS Labs (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Charles River (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck KGaA (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. \WuXi AppTec (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biomérieux SA (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Bioburden Testing Sale, by Type, Application, Testing Type, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Bioburden Testing (Value)
      • 7.2.1. Global Bioburden Testing by: Type (Value)
        • 7.2.1.1. Instruments
        • 7.2.1.2. Consumables
      • 7.2.2. Global Bioburden Testing by: Application (Value)
        • 7.2.2.1. Medical devices
        • 7.2.2.2. Pharmaceuticals
        • 7.2.2.3. Packaging
        • 7.2.2.4. Human Tissue
        • 7.2.2.5. Animal Tissue
        • 7.2.2.6. Cosmetics
      • 7.2.3. Global Bioburden Testing by: Testing Type (Value)
        • 7.2.3.1. Aerobic Count Testing
        • 7.2.3.2. Anaerobic Count Testing
        • 7.2.3.3. Fungi/Mold Count Testing
        • 7.2.3.4. Spore Count Testing
      • 7.2.4. Global Bioburden Testing by: End User (Value)
        • 7.2.4.1. Pharmaceutical & Biotechnology Companies
        • 7.2.4.2. Medical Device Manufacturers
        • 7.2.4.3. Contract Manufacturing Organizations
        • 7.2.4.4. Manufacturers of Food & Beverage and Agricultural Products
        • 7.2.4.5. Microbial Testing Laboratories
      • 7.2.5. Global Bioburden Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Bioburden Testing (Price)
      • 7.3.1. Global Bioburden Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bioburden Testing: by Type(USD Million)
  • Table 2. Bioburden Testing Instruments , by Region USD Million (2015-2020)
  • Table 3. Bioburden Testing Consumables , by Region USD Million (2015-2020)
  • Table 4. Bioburden Testing: by Application(USD Million)
  • Table 5. Bioburden Testing Medical devices , by Region USD Million (2015-2020)
  • Table 6. Bioburden Testing Pharmaceuticals , by Region USD Million (2015-2020)
  • Table 7. Bioburden Testing Packaging , by Region USD Million (2015-2020)
  • Table 8. Bioburden Testing Human Tissue , by Region USD Million (2015-2020)
  • Table 9. Bioburden Testing Animal Tissue , by Region USD Million (2015-2020)
  • Table 10. Bioburden Testing Cosmetics , by Region USD Million (2015-2020)
  • Table 11. Bioburden Testing: by Testing Type(USD Million)
  • Table 12. Bioburden Testing Aerobic Count Testing , by Region USD Million (2015-2020)
  • Table 13. Bioburden Testing Anaerobic Count Testing , by Region USD Million (2015-2020)
  • Table 14. Bioburden Testing Fungi/Mold Count Testing , by Region USD Million (2015-2020)
  • Table 15. Bioburden Testing Spore Count Testing , by Region USD Million (2015-2020)
  • Table 16. Bioburden Testing: by End User(USD Million)
  • Table 17. Bioburden Testing Pharmaceutical & Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 18. Bioburden Testing Medical Device Manufacturers , by Region USD Million (2015-2020)
  • Table 19. Bioburden Testing Contract Manufacturing Organizations , by Region USD Million (2015-2020)
  • Table 20. Bioburden Testing Manufacturers of Food & Beverage and Agricultural Products , by Region USD Million (2015-2020)
  • Table 21. Bioburden Testing Microbial Testing Laboratories , by Region USD Million (2015-2020)
  • Table 22. South America Bioburden Testing, by Country USD Million (2015-2020)
  • Table 23. South America Bioburden Testing, by Type USD Million (2015-2020)
  • Table 24. South America Bioburden Testing, by Application USD Million (2015-2020)
  • Table 25. South America Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 26. South America Bioburden Testing, by End User USD Million (2015-2020)
  • Table 27. Brazil Bioburden Testing, by Type USD Million (2015-2020)
  • Table 28. Brazil Bioburden Testing, by Application USD Million (2015-2020)
  • Table 29. Brazil Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 30. Brazil Bioburden Testing, by End User USD Million (2015-2020)
  • Table 31. Argentina Bioburden Testing, by Type USD Million (2015-2020)
  • Table 32. Argentina Bioburden Testing, by Application USD Million (2015-2020)
  • Table 33. Argentina Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 34. Argentina Bioburden Testing, by End User USD Million (2015-2020)
  • Table 35. Rest of South America Bioburden Testing, by Type USD Million (2015-2020)
  • Table 36. Rest of South America Bioburden Testing, by Application USD Million (2015-2020)
  • Table 37. Rest of South America Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 38. Rest of South America Bioburden Testing, by End User USD Million (2015-2020)
  • Table 39. Asia Pacific Bioburden Testing, by Country USD Million (2015-2020)
  • Table 40. Asia Pacific Bioburden Testing, by Type USD Million (2015-2020)
  • Table 41. Asia Pacific Bioburden Testing, by Application USD Million (2015-2020)
  • Table 42. Asia Pacific Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 43. Asia Pacific Bioburden Testing, by End User USD Million (2015-2020)
  • Table 44. China Bioburden Testing, by Type USD Million (2015-2020)
  • Table 45. China Bioburden Testing, by Application USD Million (2015-2020)
  • Table 46. China Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 47. China Bioburden Testing, by End User USD Million (2015-2020)
  • Table 48. Japan Bioburden Testing, by Type USD Million (2015-2020)
  • Table 49. Japan Bioburden Testing, by Application USD Million (2015-2020)
  • Table 50. Japan Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 51. Japan Bioburden Testing, by End User USD Million (2015-2020)
  • Table 52. India Bioburden Testing, by Type USD Million (2015-2020)
  • Table 53. India Bioburden Testing, by Application USD Million (2015-2020)
  • Table 54. India Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 55. India Bioburden Testing, by End User USD Million (2015-2020)
  • Table 56. South Korea Bioburden Testing, by Type USD Million (2015-2020)
  • Table 57. South Korea Bioburden Testing, by Application USD Million (2015-2020)
  • Table 58. South Korea Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 59. South Korea Bioburden Testing, by End User USD Million (2015-2020)
  • Table 60. Taiwan Bioburden Testing, by Type USD Million (2015-2020)
  • Table 61. Taiwan Bioburden Testing, by Application USD Million (2015-2020)
  • Table 62. Taiwan Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 63. Taiwan Bioburden Testing, by End User USD Million (2015-2020)
  • Table 64. Australia Bioburden Testing, by Type USD Million (2015-2020)
  • Table 65. Australia Bioburden Testing, by Application USD Million (2015-2020)
  • Table 66. Australia Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 67. Australia Bioburden Testing, by End User USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Bioburden Testing, by Type USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Bioburden Testing, by Application USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Bioburden Testing, by End User USD Million (2015-2020)
  • Table 72. Europe Bioburden Testing, by Country USD Million (2015-2020)
  • Table 73. Europe Bioburden Testing, by Type USD Million (2015-2020)
  • Table 74. Europe Bioburden Testing, by Application USD Million (2015-2020)
  • Table 75. Europe Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 76. Europe Bioburden Testing, by End User USD Million (2015-2020)
  • Table 77. Germany Bioburden Testing, by Type USD Million (2015-2020)
  • Table 78. Germany Bioburden Testing, by Application USD Million (2015-2020)
  • Table 79. Germany Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 80. Germany Bioburden Testing, by End User USD Million (2015-2020)
  • Table 81. France Bioburden Testing, by Type USD Million (2015-2020)
  • Table 82. France Bioburden Testing, by Application USD Million (2015-2020)
  • Table 83. France Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 84. France Bioburden Testing, by End User USD Million (2015-2020)
  • Table 85. Italy Bioburden Testing, by Type USD Million (2015-2020)
  • Table 86. Italy Bioburden Testing, by Application USD Million (2015-2020)
  • Table 87. Italy Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 88. Italy Bioburden Testing, by End User USD Million (2015-2020)
  • Table 89. United Kingdom Bioburden Testing, by Type USD Million (2015-2020)
  • Table 90. United Kingdom Bioburden Testing, by Application USD Million (2015-2020)
  • Table 91. United Kingdom Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 92. United Kingdom Bioburden Testing, by End User USD Million (2015-2020)
  • Table 93. Netherlands Bioburden Testing, by Type USD Million (2015-2020)
  • Table 94. Netherlands Bioburden Testing, by Application USD Million (2015-2020)
  • Table 95. Netherlands Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 96. Netherlands Bioburden Testing, by End User USD Million (2015-2020)
  • Table 97. Rest of Europe Bioburden Testing, by Type USD Million (2015-2020)
  • Table 98. Rest of Europe Bioburden Testing, by Application USD Million (2015-2020)
  • Table 99. Rest of Europe Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 100. Rest of Europe Bioburden Testing, by End User USD Million (2015-2020)
  • Table 101. MEA Bioburden Testing, by Country USD Million (2015-2020)
  • Table 102. MEA Bioburden Testing, by Type USD Million (2015-2020)
  • Table 103. MEA Bioburden Testing, by Application USD Million (2015-2020)
  • Table 104. MEA Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 105. MEA Bioburden Testing, by End User USD Million (2015-2020)
  • Table 106. Middle East Bioburden Testing, by Type USD Million (2015-2020)
  • Table 107. Middle East Bioburden Testing, by Application USD Million (2015-2020)
  • Table 108. Middle East Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 109. Middle East Bioburden Testing, by End User USD Million (2015-2020)
  • Table 110. Africa Bioburden Testing, by Type USD Million (2015-2020)
  • Table 111. Africa Bioburden Testing, by Application USD Million (2015-2020)
  • Table 112. Africa Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 113. Africa Bioburden Testing, by End User USD Million (2015-2020)
  • Table 114. North America Bioburden Testing, by Country USD Million (2015-2020)
  • Table 115. North America Bioburden Testing, by Type USD Million (2015-2020)
  • Table 116. North America Bioburden Testing, by Application USD Million (2015-2020)
  • Table 117. North America Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 118. North America Bioburden Testing, by End User USD Million (2015-2020)
  • Table 119. United States Bioburden Testing, by Type USD Million (2015-2020)
  • Table 120. United States Bioburden Testing, by Application USD Million (2015-2020)
  • Table 121. United States Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 122. United States Bioburden Testing, by End User USD Million (2015-2020)
  • Table 123. Canada Bioburden Testing, by Type USD Million (2015-2020)
  • Table 124. Canada Bioburden Testing, by Application USD Million (2015-2020)
  • Table 125. Canada Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 126. Canada Bioburden Testing, by End User USD Million (2015-2020)
  • Table 127. Mexico Bioburden Testing, by Type USD Million (2015-2020)
  • Table 128. Mexico Bioburden Testing, by Application USD Million (2015-2020)
  • Table 129. Mexico Bioburden Testing, by Testing Type USD Million (2015-2020)
  • Table 130. Mexico Bioburden Testing, by End User USD Million (2015-2020)
  • Table 131. Bioburden Testing: by Type(USD/Units)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Bioburden Testing: by Type(USD Million)
  • Table 143. Bioburden Testing Instruments , by Region USD Million (2021-2026)
  • Table 144. Bioburden Testing Consumables , by Region USD Million (2021-2026)
  • Table 145. Bioburden Testing: by Application(USD Million)
  • Table 146. Bioburden Testing Medical devices , by Region USD Million (2021-2026)
  • Table 147. Bioburden Testing Pharmaceuticals , by Region USD Million (2021-2026)
  • Table 148. Bioburden Testing Packaging , by Region USD Million (2021-2026)
  • Table 149. Bioburden Testing Human Tissue , by Region USD Million (2021-2026)
  • Table 150. Bioburden Testing Animal Tissue , by Region USD Million (2021-2026)
  • Table 151. Bioburden Testing Cosmetics , by Region USD Million (2021-2026)
  • Table 152. Bioburden Testing: by Testing Type(USD Million)
  • Table 153. Bioburden Testing Aerobic Count Testing , by Region USD Million (2021-2026)
  • Table 154. Bioburden Testing Anaerobic Count Testing , by Region USD Million (2021-2026)
  • Table 155. Bioburden Testing Fungi/Mold Count Testing , by Region USD Million (2021-2026)
  • Table 156. Bioburden Testing Spore Count Testing , by Region USD Million (2021-2026)
  • Table 157. Bioburden Testing: by End User(USD Million)
  • Table 158. Bioburden Testing Pharmaceutical & Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 159. Bioburden Testing Medical Device Manufacturers , by Region USD Million (2021-2026)
  • Table 160. Bioburden Testing Contract Manufacturing Organizations , by Region USD Million (2021-2026)
  • Table 161. Bioburden Testing Manufacturers of Food & Beverage and Agricultural Products , by Region USD Million (2021-2026)
  • Table 162. Bioburden Testing Microbial Testing Laboratories , by Region USD Million (2021-2026)
  • Table 163. South America Bioburden Testing, by Country USD Million (2021-2026)
  • Table 164. South America Bioburden Testing, by Type USD Million (2021-2026)
  • Table 165. South America Bioburden Testing, by Application USD Million (2021-2026)
  • Table 166. South America Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 167. South America Bioburden Testing, by End User USD Million (2021-2026)
  • Table 168. Brazil Bioburden Testing, by Type USD Million (2021-2026)
  • Table 169. Brazil Bioburden Testing, by Application USD Million (2021-2026)
  • Table 170. Brazil Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 171. Brazil Bioburden Testing, by End User USD Million (2021-2026)
  • Table 172. Argentina Bioburden Testing, by Type USD Million (2021-2026)
  • Table 173. Argentina Bioburden Testing, by Application USD Million (2021-2026)
  • Table 174. Argentina Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 175. Argentina Bioburden Testing, by End User USD Million (2021-2026)
  • Table 176. Rest of South America Bioburden Testing, by Type USD Million (2021-2026)
  • Table 177. Rest of South America Bioburden Testing, by Application USD Million (2021-2026)
  • Table 178. Rest of South America Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 179. Rest of South America Bioburden Testing, by End User USD Million (2021-2026)
  • Table 180. Asia Pacific Bioburden Testing, by Country USD Million (2021-2026)
  • Table 181. Asia Pacific Bioburden Testing, by Type USD Million (2021-2026)
  • Table 182. Asia Pacific Bioburden Testing, by Application USD Million (2021-2026)
  • Table 183. Asia Pacific Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 184. Asia Pacific Bioburden Testing, by End User USD Million (2021-2026)
  • Table 185. China Bioburden Testing, by Type USD Million (2021-2026)
  • Table 186. China Bioburden Testing, by Application USD Million (2021-2026)
  • Table 187. China Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 188. China Bioburden Testing, by End User USD Million (2021-2026)
  • Table 189. Japan Bioburden Testing, by Type USD Million (2021-2026)
  • Table 190. Japan Bioburden Testing, by Application USD Million (2021-2026)
  • Table 191. Japan Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 192. Japan Bioburden Testing, by End User USD Million (2021-2026)
  • Table 193. India Bioburden Testing, by Type USD Million (2021-2026)
  • Table 194. India Bioburden Testing, by Application USD Million (2021-2026)
  • Table 195. India Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 196. India Bioburden Testing, by End User USD Million (2021-2026)
  • Table 197. South Korea Bioburden Testing, by Type USD Million (2021-2026)
  • Table 198. South Korea Bioburden Testing, by Application USD Million (2021-2026)
  • Table 199. South Korea Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 200. South Korea Bioburden Testing, by End User USD Million (2021-2026)
  • Table 201. Taiwan Bioburden Testing, by Type USD Million (2021-2026)
  • Table 202. Taiwan Bioburden Testing, by Application USD Million (2021-2026)
  • Table 203. Taiwan Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 204. Taiwan Bioburden Testing, by End User USD Million (2021-2026)
  • Table 205. Australia Bioburden Testing, by Type USD Million (2021-2026)
  • Table 206. Australia Bioburden Testing, by Application USD Million (2021-2026)
  • Table 207. Australia Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 208. Australia Bioburden Testing, by End User USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific Bioburden Testing, by Type USD Million (2021-2026)
  • Table 210. Rest of Asia-Pacific Bioburden Testing, by Application USD Million (2021-2026)
  • Table 211. Rest of Asia-Pacific Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 212. Rest of Asia-Pacific Bioburden Testing, by End User USD Million (2021-2026)
  • Table 213. Europe Bioburden Testing, by Country USD Million (2021-2026)
  • Table 214. Europe Bioburden Testing, by Type USD Million (2021-2026)
  • Table 215. Europe Bioburden Testing, by Application USD Million (2021-2026)
  • Table 216. Europe Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 217. Europe Bioburden Testing, by End User USD Million (2021-2026)
  • Table 218. Germany Bioburden Testing, by Type USD Million (2021-2026)
  • Table 219. Germany Bioburden Testing, by Application USD Million (2021-2026)
  • Table 220. Germany Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 221. Germany Bioburden Testing, by End User USD Million (2021-2026)
  • Table 222. France Bioburden Testing, by Type USD Million (2021-2026)
  • Table 223. France Bioburden Testing, by Application USD Million (2021-2026)
  • Table 224. France Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 225. France Bioburden Testing, by End User USD Million (2021-2026)
  • Table 226. Italy Bioburden Testing, by Type USD Million (2021-2026)
  • Table 227. Italy Bioburden Testing, by Application USD Million (2021-2026)
  • Table 228. Italy Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 229. Italy Bioburden Testing, by End User USD Million (2021-2026)
  • Table 230. United Kingdom Bioburden Testing, by Type USD Million (2021-2026)
  • Table 231. United Kingdom Bioburden Testing, by Application USD Million (2021-2026)
  • Table 232. United Kingdom Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 233. United Kingdom Bioburden Testing, by End User USD Million (2021-2026)
  • Table 234. Netherlands Bioburden Testing, by Type USD Million (2021-2026)
  • Table 235. Netherlands Bioburden Testing, by Application USD Million (2021-2026)
  • Table 236. Netherlands Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 237. Netherlands Bioburden Testing, by End User USD Million (2021-2026)
  • Table 238. Rest of Europe Bioburden Testing, by Type USD Million (2021-2026)
  • Table 239. Rest of Europe Bioburden Testing, by Application USD Million (2021-2026)
  • Table 240. Rest of Europe Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 241. Rest of Europe Bioburden Testing, by End User USD Million (2021-2026)
  • Table 242. MEA Bioburden Testing, by Country USD Million (2021-2026)
  • Table 243. MEA Bioburden Testing, by Type USD Million (2021-2026)
  • Table 244. MEA Bioburden Testing, by Application USD Million (2021-2026)
  • Table 245. MEA Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 246. MEA Bioburden Testing, by End User USD Million (2021-2026)
  • Table 247. Middle East Bioburden Testing, by Type USD Million (2021-2026)
  • Table 248. Middle East Bioburden Testing, by Application USD Million (2021-2026)
  • Table 249. Middle East Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 250. Middle East Bioburden Testing, by End User USD Million (2021-2026)
  • Table 251. Africa Bioburden Testing, by Type USD Million (2021-2026)
  • Table 252. Africa Bioburden Testing, by Application USD Million (2021-2026)
  • Table 253. Africa Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 254. Africa Bioburden Testing, by End User USD Million (2021-2026)
  • Table 255. North America Bioburden Testing, by Country USD Million (2021-2026)
  • Table 256. North America Bioburden Testing, by Type USD Million (2021-2026)
  • Table 257. North America Bioburden Testing, by Application USD Million (2021-2026)
  • Table 258. North America Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 259. North America Bioburden Testing, by End User USD Million (2021-2026)
  • Table 260. United States Bioburden Testing, by Type USD Million (2021-2026)
  • Table 261. United States Bioburden Testing, by Application USD Million (2021-2026)
  • Table 262. United States Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 263. United States Bioburden Testing, by End User USD Million (2021-2026)
  • Table 264. Canada Bioburden Testing, by Type USD Million (2021-2026)
  • Table 265. Canada Bioburden Testing, by Application USD Million (2021-2026)
  • Table 266. Canada Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 267. Canada Bioburden Testing, by End User USD Million (2021-2026)
  • Table 268. Mexico Bioburden Testing, by Type USD Million (2021-2026)
  • Table 269. Mexico Bioburden Testing, by Application USD Million (2021-2026)
  • Table 270. Mexico Bioburden Testing, by Testing Type USD Million (2021-2026)
  • Table 271. Mexico Bioburden Testing, by End User USD Million (2021-2026)
  • Table 272. Bioburden Testing: by Type(USD/Units)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bioburden Testing: by Type USD Million (2015-2020)
  • Figure 5. Global Bioburden Testing: by Application USD Million (2015-2020)
  • Figure 6. Global Bioburden Testing: by Testing Type USD Million (2015-2020)
  • Figure 7. Global Bioburden Testing: by End User USD Million (2015-2020)
  • Figure 8. South America Bioburden Testing Share (%), by Country
  • Figure 9. Asia Pacific Bioburden Testing Share (%), by Country
  • Figure 10. Europe Bioburden Testing Share (%), by Country
  • Figure 11. MEA Bioburden Testing Share (%), by Country
  • Figure 12. North America Bioburden Testing Share (%), by Country
  • Figure 13. Global Bioburden Testing: by Type USD/Units (2015-2020)
  • Figure 14. Global Bioburden Testing share by Players 2020 (%)
  • Figure 15. Global Bioburden Testing share by Players (Top 3) 2020(%)
  • Figure 16. Global Bioburden Testing share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 19. Sigma-Aldrich (United States) Revenue: by Geography 2020
  • Figure 20. SGS S.A. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. SGS S.A. (Switzerland) Revenue: by Geography 2020
  • Figure 22. Becton Dickinson (United States) Revenue, Net Income and Gross profit
  • Figure 23. Becton Dickinson (United States) Revenue: by Geography 2020
  • Figure 24. Nelson Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 25. Nelson Laboratories (United States) Revenue: by Geography 2020
  • Figure 26. ATS Labs (United States) Revenue, Net Income and Gross profit
  • Figure 27. ATS Labs (United States) Revenue: by Geography 2020
  • Figure 28. Charles River (United States) Revenue, Net Income and Gross profit
  • Figure 29. Charles River (United States) Revenue: by Geography 2020
  • Figure 30. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 32. \WuXi AppTec (China) Revenue, Net Income and Gross profit
  • Figure 33. \WuXi AppTec (China) Revenue: by Geography 2020
  • Figure 34. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Biomérieux SA (France) Revenue, Net Income and Gross profit
  • Figure 37. Biomérieux SA (France) Revenue: by Geography 2020
  • Figure 38. Global Bioburden Testing: by Type USD Million (2021-2026)
  • Figure 39. Global Bioburden Testing: by Application USD Million (2021-2026)
  • Figure 40. Global Bioburden Testing: by Testing Type USD Million (2021-2026)
  • Figure 41. Global Bioburden Testing: by End User USD Million (2021-2026)
  • Figure 42. South America Bioburden Testing Share (%), by Country
  • Figure 43. Asia Pacific Bioburden Testing Share (%), by Country
  • Figure 44. Europe Bioburden Testing Share (%), by Country
  • Figure 45. MEA Bioburden Testing Share (%), by Country
  • Figure 46. North America Bioburden Testing Share (%), by Country
  • Figure 47. Global Bioburden Testing: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Sigma-Aldrich (United States)
  • SGS S.A. (Switzerland)
  • Becton Dickinson (United States)
  • Nelson Laboratories (United States)
  • ATS Labs (United States)
  • Charles River (United States)
  • Merck KGaA (Germany)
  • \WuXi AppTec (China)
  • Thermo Fisher Scientific, Inc. (United States)
  • Biomérieux SA (France)
Additional players considered in the study are as follows:
Pacific BioLlabs (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 231 Pages 75 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bioburden Testing Quantitative research analysis
Global Bioburden Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Bioburden Testing Report?

Have a Query? Click Here

Other Related Reports

Public Relations (PR) Tools Comprehensive Study by Type (Publishing Tools, Social Media Monitoring & Management, Content Creation and Distribution, Data Aggregation, Monitoring and Analysis, Relation...
$ 3750
Artificial Eye Comprehensive Study by Type (Non-Integrated Implants, Integrated Implants), Application (Hospital, Exhibition, Others, Player) Players and Region - Global Market Outlook to 2028
$ 3500
Jet Airliner Comprehensive Study by Type (Regional Airliner, Trunk-line Airliner), Application (Private, Commercial), End-User (Private, Operator), Point of Sale (OEM (Conventional & Hybrid & Electri...
$ 3750
Internet Protocol Television (IPTV) Comprehensive Study by Application (Residential Customers, Enterprise Customers), IPTV Services (Live Television & Live Media, Time-Shifted Media {Catch-up TV, sta...
$ 3750
Mannequins Market Comprehensive Study by Type (Female, Male, Child, Torso), Application (Garment Industry, Jewelry industry, Cosmetics industry), Distribution Chanel (Online, Offline), Material (Fibe...
$ 3800
Electric Baby Car Comprehensive Study by Application (Home, Commercial), Age (1 to 3 years, 3 to 6 years, Above 6 years), Speed (1 mph to 3 mph, 3 mph to 6 mph, Others), Material (Iron, Plastics, Ot...
$ 3500